Imperial Innovations and SV Life Sciences have taken part in a £25m series-A funding round to support the spin-out of UK biotech Artios Pharma from Cancer Research UK.
Imperial has invested £5.1m for a 14.9% stake in the company, while other strategic investors including Abbvie Ventures, Merck Ventures, Arix Bioscience and Sixth Element Capital also took part in the...
IPO sees Prime Ventures and Macquarie among vendors of existing shares worth a total of €153m
Business, founded in 2014, is currently at proof-of-concept stage for its product
Deal marks the GP's second divestment to an international trade buyer since the Brexit vote
Advent will merge the business with portfolio company Oberthur Technologies to form a €2.8bn group